The Company was incorporated as Emcure Pharmaceuticals Private Limited on April 16, 1981 as a private limited company under the Companies Act, 1956.

 

They are a growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Their core strength lies in developing and manufacturing differentiated pharmaceutical products in-house.

 

Their competitive advantage in the domestic market lies in their established presence in all major therapeutic areas including blood related, cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients products. They have also recently entered the oncology and diabetes therapeutic areas.

 

They focus their research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules and biosimilars, and novel drug delivery systems. They have a portfolio of 11 chiral molecules, eight of which were launched for the first time in India. They also have capabilities to develop complex products, including difficult iron preparations, oncology drugs and controlled release products. Their portfolio of in-house manufactured five commercialized biosimilars including TNK-tPA, which was launched for the first time in India.